Neurogenic dry eye associated with intravitreal injection of anti-VEGF agents

Eur J Ophthalmol. 2024 Jan;34(1):NP35-NP40. doi: 10.1177/11206721231177475. Epub 2023 Jun 23.

Abstract

Purpose: To report a case of neurogenic dry eye (NDE) that developed after intravitreal ranibizumab injection (IVR).

Case report: A 71-year-old woman had a history of cataract phacoemulsification and intraocular lens (IOL) implantation, Nd:YAG laser posterior capsulotomy and femtosecond laser-assisted laser in situ keratomileusis (FS-LASIK). Aneurysmal dilatation of the inferior temporal retina was found in the left fundus, which was diagnosed as retinal aneurysm, and intravitreal ranibizumab injection was administered. Dry eye was found in the left eye after the first injection. After the second injection, the patient developed severe dry eye with left eye dryness, photophobia, irritation, and blurred vision. The tear film breakup time (TBUT) value was 3 s, the Schirmer test value was 2 mm/5 min, corneal fluorescein staining (CFS) showed diffuse patellar staining of the corneal epithelium with a staining area of >50% and irregular staining at the edge of the corneal flap, and the corneal touch threshold value in the filament length was 1.5 cm in the left eye.

Conclusions: Patients with a history of intraocular lens implantation, Nd:YAG laser posterior capsulotomy, and femtosecond laser-assisted laser in situ keratomileusis surgery may have increased drug permeability due to an increased concentration of anti-VEGF drugs in the aqueous layer and thinning of the stromal layer of the cornea. The corneal subepithelial nerve repair mechanism was destroyed, causing neurogenic dry eye.

Keywords: femtosecond laser-assisted laser in situ keratomileusis; intravitreal ranibizumab injection; nd:YAG laser posterior capsulotomy; neurogenic dry eye; retinal aneurysm.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Angiogenesis Inhibitors* / administration & dosage
  • Angiogenesis Inhibitors* / adverse effects
  • Dry Eye Syndromes* / diagnosis
  • Dry Eye Syndromes* / etiology
  • Dry Eye Syndromes* / pathology
  • Fundus Oculi
  • Humans
  • Intravitreal Injections
  • Ranibizumab* / administration & dosage
  • Ranibizumab* / adverse effects
  • Vascular Endothelial Growth Factor A* / antagonists & inhibitors